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of administration” was less important for participants (coef.: 0.141). ConClusions: 
“Progression-free survival” and “tumor-associated symptoms” were identified as key 
patient-relevant characteristics in this study. The sole consideration of the “progres-
sion-free survival” as foundation for decisions is not sufficient from the patients’ 
perspective and multiple criteria are important. Subgroup analysis revealed that the 
importance of “progression-free survival” increases with increased therapy experi-
ence. Basically, the results give insight into how much a deciding factor affects the 
treatment decision from the perspective of patients. In addition, the results of this 
survey can provide a basis for patient-oriented evaluation of treatment options 
in NSCLC.
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Carer PerCeived BurdeN as a PrediCtor of HealtH-related Quality of 
life: tHe Case of ColoreCtal CaNCer
Hanly P.1, Maguire R.1, Hyland P.1, Sharp L.2
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objeCtives: This study aimed to (i) investigate the impact of subjective and objective 
factors on colorectal cancer carer physical and mental health, and (ii) identify key 
subjective burden predictors of these two domains. Methods: 228 colorectal can-
cer survivors diagnosed October 2007–September 2009 nominated an informal carer. 
Carers were posted a questionnaire which included questions on socio-demographic 
characteristics, relationship with the care recipient, the caregiver reaction assess-
ment (CRA) scale and the SF-12v2. Multivariate linear regression was used to assess 
whether five CRA domains (family support, finances, schedule and health, esteem) 
predicted carer mental or physical health, controlling for age and other confound-
ers. Results: 153 carers (82% female) completed the questionnaire (response rate = 
68%). Carers’ mean physical component score (PCS) was 48.56 (SD= 10.38) and mean 
mental component score (MCS) was 49.22 (SD= 9.7). The most negatively affected 
CRA domain was disrupted schedule (mean= 3.0), followed by financial problems 
(mean= 2.4), health problems (mean= 2.3) and lack of family support (mean= 2.0). 
Multiple regression analysis showed health burden was the strongest predictor (β = 
-.54, p < .001) of carer PCS, followed by having a comorbid condition (β = -.34, p < .001), 
age (β = -.33, p < .001) and schedule burden (β = .25, p = .008). MCS was significantly 
predicated by financial problems (β = -.20, p = .02), age (β = -.16, p = .05) and esteem (β 
= -.16, p = .05). ConClusions: Our results demonstrate the need to recognise the dif-
ferent aspects of the impact of caring on caregivers (i.e. physical and mental), and that 
different domains of subjective caregiver burden impact differently on each of these.
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imPaCt of BraiN metastases oN Quality of life aNd estimated life 
exPeCtaNCy iN PatieNts witH advaNCed NoN-small Cell luNg CaNCer
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The majority of patients with Non-Small Cell Lung Cancer (NSCLC) are diagnosed 
with advanced disease (Stage IV). The site of the metastasis as well as the underly-
ing disease influences the outcome and the patient’s quality of life. objeCtives: 
To evaluate the impact of brain metastases compared with other metastatic sites 
on health-related quality of life (EQ-5D) and physician-perceived life expectancy 
in stage IV NSCLC patients. Methods: Data were drawn from the Adelphi NSCLC 
Disease-Specific Programme (DSP®), a cross-sectional survey of 120 pulmonologists 
and oncologists and their NSCLC patients conducted between July and September 
2010 in France and Germany. Each physician completed detailed record forms on 
10 advanced patients being actively treated for NSCLC. Patients were invited to 
complete an equivalent patient self-completion questionnaire (PSC) which included 
the EQ-5D. Analysis was conducted on patients with only one metastatic site, either 
brain, contralateral lung, adrenal gland, bone or liver. Mann-Whitney tests were 
used to assess the differences between metastatic sites. Results: 498 patients 
with one metastatic site were identified of whom 325 (65%) completed a PSC. The 
higher the EQ-5D score the better the health state, EQ-5D was significantly lower 
for patients with brain metastases (mean 0.52, n= 29) compared with contralateral 
lung metastases (0.69, n= 111, p= 0.0196); adrenal glands (0.83, n= 43, p= 0.0001) and 
liver (0.71, n= 46, p= 0.0191). No significant difference was observed between brain 
and bone metastases (0.53, n= 92, p= 0.8219). Estimated life expectancy was signifi-
cantly shorter for brain metastases (25.3 weeks) compared with contralateral lung 
(50.5 weeks), bone (49.4 weeks), adrenal glands (48.7 weeks) and liver (44.9 weeks) 
(all p< 0.01). ConClusions: The development of brain metastases in patients with 
advanced NSCLC is associated with a significant reduction in quality of life and 
estimated life expectancy compared with other metastatic sites.
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objeCtives: Men with mCRPC are at risk of experiencing SREs, defined as patho-
logic bone fracture (“fracture”), spinal cord compression (“compression”), and the 
need for radiotherapy or surgery to bone (“radiotherapy/surgery”). We examined the 
patient and clinical relevance of SREs for HRQoL in men with mCRPC. Methods: 
We analysed data from patients experiencing any type of SRE (n= 587; irrespective of 
treatment) in PREVAIL - a phase 3 trial of enzalutamide (n= 872) vs. placebo (n= 845) 
in asymptomatic/mildly symptomatic chemo-naïve mCRPC patients. For patients 
with multiple SREs, only the first event was included. HRQoL was assessed using 
the FACT-P and EQ-5D tools. Impact of first SRE on HRQoL was evaluated as follows: 
especially in comparative and longitudinal studies is recommended in order to 
enhance use of BQ in clinical decision making around BR modalities.
PCN201
PatieNts’ Priorities iN tHe treatmeNt of NeuroeNdoCriNe tumors: aN 
aNalytiC HierarCHy ProCess
Mühlbacher A.C., Juhnke C., Kaczynski A.
Hochschule Neubrandenburg, Neubrandenburg, Germany
objeCtives: Neuroendocrine tumors (NET) are relatively rare, usually slow-growing 
malignant tumors. So far there is no data on the patient preferences/priorities 
regarding the therapy of NET. This empirical study aimed at the elicitation of patient 
priorities in the drug treatment of NET. Methods: Qualitative patient interviews 
(N= 9) were conducted. To elicit patient’s perspective regarding various treatment 
aspects of NET a self-administered questionnaire using Analytic Hierarchy Process 
(AHP) was developed. The data collection was carried out using paper question-
naires supported by an item response system in a group discussion. To evaluate 
the patient-relevant outcomes, the eigenvector method was applied. Results: 
N= 24 patients, experts and relatives participated in the AHP survey. In the AHP all 
respondents had clear priorities for all considered attributes. The attribute “overall 
survival” was the most significant feature of a drug therapy for all respondents. As 
in the qualitative interviews, “efficacy attributes” dominated the side effects in the 
AHP as well. The evaluation of all participants thus showed the attributes “overall 
survival” (Wglobal: 0.418), “progression free survival” (Wglobal: 0.172) and “response 
to treatment” (Wglobal: 0.161) to be most relevant. “Occurrence of abdominal pain” 
(Wglobal: 0.051) was ranked last, with “tiredness/fatigue” and “risk of a hypoglyce-
mia” (Wglobal: 0.034) on a shared seventh place. ConClusions: The results thus 
provide evidence about how much influence a treatment capacity has on therapeu-
tic decision. Using the AHP major aspects of drug therapy from the perspective of 
those affected were captured, and positive and negative therapeutic properties could 
be related against each other. Based on the assessment of the patient’s perspective 
further investigation must elicit patient preferences for NET drug therapy. In the 
context of a discrete choice experiment or another choice -based method of prefer-
ence measurement, the results obtained here can be validated and the therapeutic 
features weighted according to their preferability.
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wHat relaPsed/refraCtory Cll/mCl treatmeNt outComes do germaN 
PatieNts aNd PHysiCiaNs fiNd most imPortaNt? results from 
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objeCtives: Despite the availability of a wide number of treatments for relapsed/
refractory (r/r) chronic lymphocytic leukemia (CLL) and r/r mantle cell lymphoma 
(MCL), no standard of care has emerged. There are no studies evaluating preferences 
for treatment outcomes for r/r CLL and r/r MCL. This study was designed to elicit 
preferences for r/r MCL and r/r CLL treatment outcomes among patients, the general 
public and physicians experienced in treating CLL/MCL in Germany. Methods: 
Interviews (90 minutes) in German of 6 CLL/6 MCL hematologists, 6 r/r CLL and 5 r/r 
MCL patients were conducted (total 23 interviews). Participants were asked to state 
their most important treatment outcomes. Transcripts were translated to English 
and analyzed by counting the number of times each outcome was mentioned. 
We present here results of patient and physician preferences. Results:  r/r CLL 
patients mention overall survival (OS; 5 counts), mode of treatment administration 
(4), quality of life (QOL) aspects (4) and progression free survival (PFS) disease control 
(4). A tolerable side effect (SE) profile/controlling disease symptoms was mentioned 
by 3 patients. Other treatment outcomes were infections, nausea (2 each), fatigue, 
weight loss, pain, fever, polyneuropathy and long treatment intervals (1 each). CLL 
physicians mentioned OS (4), QOL (4) and PFS (4). r/r MCL patients mentioned effi-
cacy benefits such as cure (4) and OS (2), PFS (1); various QOL aspects (5) and a 
tolerable SE profile/controlling disease (3). Other treatment outcomes were long-
term organ damage (2), hair loss, nausea and night sweat (1 each). MCL physicians 
mentioned OS (6), QOL (5) and a tolerable SE profile (4). ConClusions: Extending 
life, disease control, maintaining QOL and avoiding SE are important r/r MCL/CLL 
treatment outcomes to German patients and physicians.
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PatieNts’ PrefereNCes iN late stage treatmeNt of NoN-small-Cell 
luNg CaNCer: a disCrete-CHoiCe exPerimeNt
Mühlbacher A.C.1, Bethge S.2
1University of Applied Sciences Neubrandenburg, Neubrandenburg, Germany,, 2Hochschule 
Neubrandenburg, Neubrandenburg, Germany
objeCtives: Lung cancer is a major cause of cancer-related deaths and thus rep-
resents a global health problem. To date, decisions on which treatment to use are 
often driven by health care professionals’ opinions. The perspective of patients 
with metastatic non-small cell lung cancer (NSCLC) on the importance of different 
treatment criteria and the ranking of these decision criteria are rarely taken into 
consideration. Aim of the study is the evaluation of patients’ preferences for differ-
ent treatment characteristics of NSCLC patients. Methods: The literature review 
and 10 qualitative interviews revealed seven patient-relevant treatment attributes. A 
Discrete-Choice Experiment (DCE) was used to rank the patient-relevant treatment 
characteristics. The DCE was conducted using a fractional factorial design (Ngene) 
and the statistical data analysis used random effect logit and GLLAMM latent 
class models for subgroup identification. Results: In total N= 211 patients with 
metastatic NSCLC participated in the computer-assisted personal interviews. The 
estimation revealed a clear dominance for “progression-free survival” (coef.: 1.087) 
and “tumor-associated symptoms (cough, shortness of breath and pain)” (coef.: 
1.090), followed by the side effects: “nausea and vomiting” (coef.: 0.605), “rash” (coef.: 
0.432), “diarrhea” (coef.: 0.427) and “tiredness and fatigue” (coef.: 0.423). The “mode 
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of life (QoL) and the ability to work (WA) too. Till now in the Slovak Republic there 
was not realised the study oriented on the both mentioned categories. Methods: 
102 patients with LC were studied. The average of age was 50.3 y., weight – 78.3 kg, 
height – 175.1, duration of illness – 2.4 y., symptoms of illness before diagnosis – 1.2 
y. Metastases were present in 72 patients. 4 patients were mentioned as strong pes-
simists, 10 predominant pessimists, 9 neither pessimists nor optimists, 61 predomi-
nant optimists, and 18 strong optimists. QoL and the ability to work was evaluated 
by means of the numeric scale from 0 to 10 (0-the worst, 10- the best) by patients 
themselves. Results: The QoL was evaluated in these domains: in the time of good 
health – 8-21, in the time of diagnosis – 2.82, in the current time – 3.71. The WA had 
these results: in time of good health – 8.89, in the time of diagnosis – 5.08, and in 
the current time – 2.17. The impact of treatment on the QoL was 2.49 and on the 
patients families QoL it was 2.75. The willingness to pay for perfect cure was 92.35 € 
per month (the average salary in Slovakia in 2013 was 824 € ). ConClusions: LC has 
a great impact on QoL and on the WA too. There was a strong correlation between 
QoL and WA, although the WA has the later onset as QoL. Our research confirmed 
the importance of early diagnosis and high effective treatment of this disease.
PCN210
validatioN of tHe ProPosed reduCed Quality of life QuestioNNaire 
to tHe eortC QlQ-C30 iN CuBaNs PatieNts witH CaNCer
Viada C.
Center of Molecular Immunology, Havana, Cuba
objeCtives: To validate the short version of the QLQ-C30 obtained for patients with 
non-small-cell lung cancer in patients with head and neck, prostate, breast or cervix 
cancer. Methods: We analysed data of 636 patients distributed: 237 diagnosed 
with head and neck cancer, 146 diagnosed with breast cancer, 140 diagnosed with 
cervix cancer and 113 diagnosed with prostate cancer. The analysis followed a 4-step 
approach. First, we conducted a Mokken nonparametric item response analysis 
to ascertain the QLQ-C30 dimensionality and separate several scale if appropri-
ate. Second, we conducted a parametric Samejima’s graded response model (GRM) 
to assess the item characteristics and information for each scale. Third, we did 
a confirmatory factor analysis (CFA) to test the scales unidimensionality and to 
obtain standardised factor loadings to suggest a reduced version of the QLQ. Finally, 
we assessed the discriminative validity of the reduced version by using receiver-
operator curve (ROC) analysis. Results: Mokken analysis of the QLQ-C30 resulted 
in a unidimensional scale, with an overall scalability defined a medium scale. The 
unconstrained GRM showed that most items presented appropriate difficulty and 
discrimination parameters. The CFA supported an underlying unidimensional 
latent structure for the whole QLQ-C30 (CFI = 0.98; RMSEA = 0.05) with modifica-
tion indexes pointing to important redundancy of information. The selection of 
items with standardized factor loadings > 0.70 lead to a 6-item QLQ that showed 
good discriminative validity against independent criteria of quality of life (ROC 
area = 0.76; 95% CI = 0.72 to 0.80) as compared with the values for the whole scale 
(ROC area = 0.70; 95% CI = 0.66 to 0.74). ConClusions: The EORTC reduced scale 
was validated in this study; it presents good psychometric properties and includes 
a unidimensional structure of patient-perceived quality of life.
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sHared deCisioN-makiNg iN womeN witH early stage Breast CaNCer 
aNd imPliCatioNs for loNg-term HealtH-related Quality of life
Scott A.M.1, Jhanwar S.M.1, Pusic A.2, McCarthy C.M.1
1Memorial Sloan Kettering Cancer Center, New York, NY, USA, 2Memorial Sloan-Kettering Cancer 
Center, New York, NY, USA
objeCtives: Surgery for breast cancer has a substantial impact on a woman’s 
health-related quality of life (HR-QOL). The NIH and EORTC advocate treatment 
with breast conserving therapy (BCT) for women with early stage breast cancer. The 
aim of this study was to understand the shared surgical decision-making process 
from the patients’ perspective by implementing qualitative methods. Methods: 
All participants were recruited and consented from a single center. Inclusion criteria 
included women who selected BCT over mastectomy. Utilizing an interview guide, 
women were asked to share their experience with all aspects of decision-making 
related to breast cancer treatment. Interviews were audio-taped, transcribed, and 
coded with NVIVO8. Qualitative data were further analyzed to identify factors 
influencing decision-making regarding BCT. A comparative matrix analysis was 
conducted to further evaluate women’s appraisal of their surgical decision-mak-
ing process and how this impacted their long-term HR-QOL. Results: Nineteen 
patients were included in the analysis. The mean age was 58.3 (+ 12.2) years, 52.9% 
were married, 84.2% were Caucasian, 68.4% were currently employed and 31.6% 
had a family history of breast cancer, 10.4% diagnosed with Stage 0, 52.6% stage 
I and 36.8% stage II breast cancer. Factors contributing to decision-making were 
dichotomized into satisfied (n= 11) or dissatisfied (n= 8). Satisfied patients were 
further categorized as either (i) positive outlook n= 2; (ii) acceptance of choice n= 9; 
Dissatisfied patients were further categorized as (i) experiencing regret n= 4; (ii) fear 
of recurrence n= 4. ConClusions: As decision-making needs vary by individual 
women, a personalized decision-making approach is an essential factor to improve 
HR-QOL among women with early stage breast cancer. Additional prospective quan-
titative studies of the preoperative decision-making and post-operative HR-QOL are 
necessary, as these findings may compliment existing outcomes research.
CaNCer – Health Care use & Policy studies
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evideNCe-Based mediCiNe as a driver of imProviNg ColoreCtal 
CaNCer sCreeNiNg iN ukraiNe
Rubtsova I.1, Melnyk Y.2
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1) estimate each patient’s longitudinal HRQoL trajectory before the first SRE using 
repeated measures analysis; 2) calculate how SREs affect HRQoL changes. Results: 
We found statistically significant declines in utility scores after all three types of 
SREs with an adjusted mean change of -0.06 (95% CI [-0.10, -0.02]) for “radiotherapy/
surgery” (N= 107), -0.20 (95% CI [-0.36, -0.04]) for “fractures” (N= 31) and -0.24 (95% 
CI [-0.39, -0.08]) for “compression” (N= 23). “Fractures” and “compression” affected 
a number of FACT-P domains and total score to a clinically meaningful and statisti-
cally significant extent. Compression had the broadest impact, affecting 7 out of 9 
FACT-P domains and induced a mean decrease in the FACT-P total score of -16.96 
(95% CI [-26.47, -7.44]). Radiotherapy/surgery was associated with a statistically 
significant decline in physical (-1.28, 95% CI [-2.06, -0.50]) and functional well being 
(-1.51, 95% CI [-2.37, -0.64]), and improvement in social well being (1.26, 95% CI [0.60, 
1.91]). Full results will be presented. ConClusions: The presence of SREs was 
significantly associated with poorer HRQoL in this patient population. Any therapy 
reducing or delaying the occurrence of SREs may slow down the observed HRQoL 
decline in mCRPC patients.
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sustaiNaBle measuremeNt of resPoNse sHift iN Prostate CaNCer 
PatieNts: adjustiNg HealtH related Quality of life witH tHe  
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objeCtives: Patients diagnosed with prostate cancer (PCa) have similar survival 
rates across treatments, making treatments choices based on health related quality 
of life (HRQoL) more important. Objective was to increase HRQoL usage, sustain-
ability and reliability measurement over time for use in cost–effectiveness analyses 
by investigating the occurrence of response shift (RS) in PCa patients. Never before 
has RS been measured over this long a time in PCa patients, not limited by few 
available treatment options. Methods: A prospective cross sectional cohort study 
was started in January of 2012 with 1,720 CAPSURE patients using the SF-36 and 
UCLA-Prostate Cancer Index (PCI). In January of 2012 patient were asked to fill out 
questionnaires asking about their perceived HRQoL at time of diagnosis (then score) 
and current HRQoL (post-score). These scores were matched to previous collected 
scores at baseline (pre-score), ranging from 3 months to 20 years. RS (then-pre score), 
True Change (TC= post-then score) and Felt Change (FC= post-then) were calculated 
and compared with t-tests in different questionnaire domains. Linear regression 
was used to explore relations between scores and patient characteristics. Results: 
RS and FC are found to be negative overall for SF-36 (RS:-3.6/-14.5 TC:-8.1/1.8 
FC:-3.0/-22.7) and PCI (RS:-4.0/-30.2 TC:-20.2/0.07 FC:-3.6/-49.8), showing significant 
difference (P< 0.05). Significant difference was also seen over the whole time range 
between post-scores and RS-adjusted-post-scores for SF-36 and PCI. A difference 
was found between recurrence and non-recurrence in both questionnaires (ranging 
0/-4.0), although not significant. RS over time did not show change. ConClusions: 
Mean negative RS scores were found in this population using SF-36 and PCI, indi-
cating over reporting in retrospective collected data. It is recommended physicians 
and researchers adjust found HRQoL scores with RS values found in this study, 
to increase usage, sustainability and reliability of retrospective collected HRQoL-
scores. Further research is needed to investigate RS dependency on other variables 
or characteristics.
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Quality of life iN PatieNts witH multiPle myeloma iN slovakia
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objeCtives: Multiple myeloma is common in older adults and its incidence increases 
after the age of 60 (under the age of 40, it occurs rarely, < 2%). In SK approx. 400 new 
cases have been diagnosed and in the treatment there is in average 1500 patients. 
Research aim was to find out the impact of the disease on particular items of Quality 
of patients´ lives. Methods: Sample: research consisted of pacienti diagnosed with 
the disease of multiple myeloma. We distributed 120 questionnaires and compiled 82 
questionnaires (68,33%). There were 36 men (43,90%) and 46 women (56,10%). Their age 
was between 40 and more. We utilised standardised questionnaire of quality of life, 
Quality of Life-BREF (WHOQOL-BREF). Its first part included 24 items in four domains 
(physical health, psychological health, social relationships, and environment) and two 
items of overall evaluation. Numerical scales were signed in the answers in the follow-
ing way: the least auspicious answer had the smallest value and the most auspicious 
answer had the biggest numerical value (range 1 – 5). The results of respondents were 
compared to population norms of the WHOQOL-BREF domains. Results: In majority 
of items, the answers of the respondents do not differ very much in comparison with 
the average score of WHOQOL-BREF. Two items mostly differ from the average score 
most: domain of physical health – pain, where the average of 2.5 lowered in compari-
son to population norm of 4.03. The domain psychological health – negative emo-
tions: where the average of 2.00 was lower in comparison to the population norm of 
3.47. ConClusions: Prompt diagnostics of multiple myeloma significantly increases 
the possibility of the treatment to be successful. It also prolongs and improves quality 
of patient life. Research finding points out the reality that MM does not have the same 
impact on all domains of quality of life.
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Quality of life iN PatieNts witH luNg CaNCer iN tHe slovak rePuBliC
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1Trencin University, Trencin, Slovak Republic, 2Trencin University of Alexander Dubcek, Trencin, 
Slovak Republic
objeCtives: The current incidence and mortality of lung cancer (LC) in adult 
patients in Slovakia ranges from about 57.3 resp. 50.3 in men and 10.6 resp. 7.6 
in women per 100000 inhabitants. The lung cancer has a great impact on quality 
